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Introduction: A major pathophysiologic mechanism in sepsis is impaired host immunity which results in failure to
eradicate invading pathogens and increased susceptibility to secondary infections. Although many
immunosuppressive mechanisms exist, increased expression of the inhibitory receptor programmed cell death 1
(PD-1) and its ligand (PD-L1) are thought to play key roles. The newly recognized phenomenon of T cell exhaustion
is mediated in part by PD-1 effects on T cells. This study tested the ability of anti-PD-1 and anti-PD-L1 antibodies to
prevent apoptosis and improve lymphocyte function in septic patients.
Methods: Blood was obtained from 43 septic and 15 non-septic critically-ill patients. Effects of anti-PD-1, anti-PD-L1,
or isotype-control antibody on lymphocyte apoptosis and interferon gamma (IFN-γ) and interleukin-2 (IL-2) production
were quantitated by flow cytometry.
Results: Lymphocytes from septic patients produced decreased IFN-γ and IL-2 and had increased CD8 T cell expression
of PD-1 and decreased PD-L1 expression compared to non-septic patients (P<0.05). Monocytes from septic
patients had increased PD-L1 and decreased HLA-DR expression compared to non-septic patients (P<0.01). CD8
T cell expression of PD-1 increased over time in ICU as PD-L1, IFN-γ, and IL2 decreased. In addition, donors with
the highest CD8 PD-1 expression together with the lowest CD8 PD-L1 expression also had lower levels of HLA-DR
expression in monocytes, and an increased rate of secondary infections, suggestive of a more immune exhausted
phenotype. Treatment of cells from septic patients with anti-PD-1 or anti-PD-L1 antibody decreased apoptosis
and increased IFN-γ and IL-2 production in septic patients; (P<0.01). The percentage of CD4 T cells that were
PD-1 positive correlated with the degree of cellular apoptosis (P<0.01).
Conclusions: In vitro blockade of the PD-1:PD-L1 pathway decreases apoptosis and improves immune cell function in
septic patients. The current results together with multiple positive studies of anti-PD-1 and anti-PD-L1 in animal models
of bacterial and fungal infections and the relative safety profile of anti-PD-1/anti-PD-L1 in human oncology trials to date
strongly support the initiation of clinical trials testing these antibodies in sepsis, a disorder with a high mortality.* Correspondence: hotch@wustl.edu
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Although most new therapeutic approaches to sepsis
have focused on blocking the early hyper-inflammatory
phase, recent studies have highlighted the profound
immunosuppressive state that occurs after the initial
stage of the disorder [1-4]. Numerous interacting
mechanisms of immunosuppression occur in sepsis,
including increased T regulatory cells, increased mye-
loid derived suppressor cells, apoptotic depletion of
immune effector cells, and a shift from a TH1 to an
anergic or TH2 immune phenotype [5-8]. Another re-
cently recognized mechanism of immunosuppression
in sepsis is T cell exhaustion [3]. T cell exhaustion
was first described in states of chronic viral infection
with persistent high levels of antigen exposure [9-11].
It is typified by the presence of T cells which have
lost effector function, that is, they fail to proliferate,
produce cytokines or induce cytotoxic cell death in
targeted cells [10]. Exhausted T cells also have an
increased tendency to undergo apoptosis because of
changes in the ratio of pro- and anti-apoptotic Bcl-2
family members. One of the contributing factors for
development of T cell exhaustion is signaling by the
negative co-stimulatory molecule PD-1 (CD279), a
member of the B7-CD28 super family, following
interaction with its ligands PD-L1 (CD274) and PD-
L2 (CD273) [9,11-13]. Following T cell activation, PD-1 is
promptly induced and subsequently expressed on the
surface of CD4 and CD8 T cells whereupon it interacts
with PD-L1 and PD-L2. PD-L1 is broadly expressed
on both hematopoietic and non-hematopoietic cells
and its expression is significantly up-regulated during
states of inflammation such as sepsis [11].
Although much of the focus and excitement of anti-
PD-1 antibody therapy has been in the field of oncology,
in which it has been demonstrated to be highly effective
in inducing remissions in patients with a variety of
malignancies [14,15], anti-PD-1 has also shown signifi-
cant success in infectious disease. Multiple independ-
ent investigators have reported that blockade of the
PD-1:PD-L1 pathway restores T cell effector function,
increases IFN-γ production, prevents apoptosis and
improves survival in various pathologic models of
sepsis [16-20]. The present study compared and con-
trasted the ability of anti-PD-1 and anti-PD-L1 anti-
bodies to decrease apoptosis and improve effector
function in leukocytes from patients with sepsis. An-
other goal of the study was to determine if a correlation
existed between lymphocyte apoptosis and putative
mediators of apoptosis including lymphocyte PD-1 and
PD-L1 expression and monocyte PD-L1 expression to
gain insight into possible mechanisms for apoptotic




Patients at Barnes Jewish Hospital who were older than
18 years of age and who fulfilled a consensus panel
definition of sepsis [21] were included in the study
(Table 1). Sepsis was defined as the presence of systemic
inflammatory response syndrome (SIRS) and a known or
suspected source of infection. Patients with HIV infection,
viral hepatitis, or who were receiving immunosuppressive
medications (except corticosteroids at a dose of <10 mg
prednisone or equivalent per day) were excluded. Consent
for blood draws was obtained from the patient or a legally
authorized representative.
Critically-ill non-septic patients
Control subjects consisted of critically-ill non-septic
patients admitted to the ICU for care following major
surgery, trauma or myocardial ischemia (Table 1). Ex-
clusion criteria were identical to that for patients with
sepsis. Consent for blood draws was obtained from the
patient or a legally authorized representative.
All protocols were approved by the Washington Univer-
sity Institutional Review Board.
Blood collection and processing
Patients provided consent for a maximum of four blood
samples (5 ml/sample) obtained serially at days 1 to 3
after admission to the ICU (‘A’), days 4 to 7 (second
blood draw, ‘B’), days 8 to 12 (third blood draw, ‘C’), and
days 13 to 21 (fourth blood draw, ‘D’) after sepsis onset.
The same serial blood draw protocol was used in non-
septic patients. Heparinized blood was collected through
an indwelling central venous or arterial catheter or by
peripheral venipuncture. The blood was immediately
transported and processed in the laboratory. Peripheral
blood mononuclear cells (PBMCs) were isolated by dens-
ity gradient separation. Plasma was collected and stored
at -80°C for subsequent analysis. The cells were washed
and resuspended in RPMI 1640 and processed for immu-
nostaining or overnight incubation as previously described.
Flow cytometry
Antibodies for flow cytometric determinations were
purchased from BioLegend (San Diego, CA, USA), BD
Biosciences (San Diego, CA, USA) or eBiosciences (San
Diego, CA, USA). Cellular expression of PD-1 and PD-
L1 on acutely isolated PBMCs was performed on the
day of blood draw. Lymphocytes were identified by
forward scatter (FSC) and side scatter (SSC) properties as
described previously [3]. Monocytes were identified by
FSC and SSC properties and by CD14+ immunostaining.
T cell subsets were further identified by CD3+, CD4+ or
CD8+ immunostaining. NK cells were identified as CD3-/
Table 1 Patient characteristics
Septic Non-septic
# Patient 43 15
Age
Median 64 53

























IQR 0.74 to 1.65 0.6 to 1.0
Length of ICU stay
Median 10 5
IQR 6 to 16 2 to 16
Mortality (%)
Survived 34 (79) 13 (87)

























Heart disease 35 14
Morbid obesity 2 0
Neurologic 6 3
Renal disease 6 0
Respiratory 14 2
Liver 1 0
ALC, absolute lymphocyte count; APACHE II, Acute Physiology and Chronic
Health Evaluation II; INR, International Normalized Ratio; IQR, Interquartile
range; SOFA, Sequential Organ Failure Assessment.
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as CD3+/CD56 + .
Effects of anti-PD-1 and anti-PD-L1 on
lymphocyte apoptosis
A total of approximately 1 × 107 cells were incubated over-
night. Cells were treated with either isotype-control
antibody, anti-PD-1 antibody or anti-PD-L1 antibody.
Anti-PD-1 antibody and anti-PD-L1 antibody were pro-
vided by MedImmune and were all human IgG1. The effect
of anti-PD-1 and anti-PD-L1 antibody on lymphocyte
apoptosis following overnight incubation was quanti-
tated via the TUNEL assay as previously described [18].
Effects of anti-PD-1 and anti-PD-L1 on stimulated IFN-γ
and IL-2 production
PBMCs that had undergone overnight incubation with
either isotype-control antibody, anti-PD-1 antibody or anti-
PD-L1 antibody were stimulated with PMA/ionomycin plus
brefeldin for 5 h as previously described [22,23]. Following
stimulation, cells were washed, stained with anti-CD3
and anti-CD56 antibodies, fixed with 1% paraformalde-
hyde, permeabilized with 1X perm/wash (BioLegend) and
stained with fluorescently labeled anti-IFN-γ or anti-IL-2
antibodies.
Patient hematologic values
Depending upon severity of illness, ICU patients have
daily complete blood count analysis performed as part
of the standard of care. Patient clinical laboratory values
that were recorded in this study included absolute
lymphocyte, absolute monocyte, and absolute granu-
locyte cell counts and were quantitated in the clinical
laboratories at Barnes Jewish Hospital (see Additional
file 1: Table S1).
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Secondary infections
Data on nosocomial infections occurring while patients
were in the ICU were abstracted from medical records
using standard Center for Disease Control case definitions
(www.cdc.gov/hai/). Identification of secondary infections
was performed by an individual who was blinded to
patient stratification.
Consent
Written informed consent was obtained from the patient
or, if the patient was unable to provide consent, their
relative for publication of their individual details and
accompanying images in this manuscript. The consent
form is in the patients’ clinical notes and a copy is also
held by the authors and is available for review by the
Editor-in-Chief.
Statistical analysis
Data were analyzed with the statistical software Prism
(GraphPad, San Diego, CA, USA). Data are reported as the
mean ± SEM. For comparison of two groups, the Student’s
t-test was employed. A paired t-test was used when com-
paring samples from the same patient which were treated
identically except for incubation with either anti-PD-1
or anti-PD-L1 antibodies. One-way ANOVA with Tukey’s
multiple comparison tests was used to analyze data in
which there were more than two groups. Significance was
reported at P <0.05.
Results
Patient demographics
Relevant clinical and laboratory values for septic and
critically-ill non-septic patients regarding median age,
gender, sites of infection, severity of illness scores, mortal-
ity, length of ICU stay and so on are provided in Table 1.
Additional patient data are presented in Additional file 1:
Table S1 and Additional file 2: Table S2. A total of 43
septic patients were included in the study. Thirty-nine
of the 43 septic patients were located in ICUs; 3 septic
patients were located in lesser acuity treatment areas
including observation units. Fifteen critically-ill non-septic
patients were included in the study. Two non-septic
critically-ill patients became septic with ventilator-associated
pneumonia during their initial ICU admission. Data
from these two patients are included in both septic and
non-septic columns based upon their particular phase of
illness, that is, non-septic or septic phase. Most non-septic
patients did not remain in the ICU past four days and
therefore, only one blood draw was obtained in these pa-
tients. Mortality in the septic and critically-ill non-septic
patients was 21% and 13%, respectively (Table 1). The
most common causes of sepsis were community acquired
pneumonia and peritonitis (Table 1).Sepsis increased CD8 PD-1 and monocyte PD-L1 expression
Examination of PD-1 expression on CD4 and CD8 T
cells showed that sepsis caused an increase in CD8 but
not CD4 PD-1 expression compared to non-septic patients
(Figure 1, Additional file 3: Figure S1). The percentage of
monocytes that were expressing PD-L1 was increased over
two-fold in septic versus non-septic patients (Figure 1). As
is characteristically described in patients with sepsis [4],
monocyte HLA-DR expression was significantly decreased
in septic versus non-septic patients, P <0.001, (Figure 1).
Monocyte HLA-DR expression remained depressed
throughout the duration of sepsis (Additional file 4:
Figure S2). Similarly, PD-L1 on monocytes from septic
patients remained elevated but did not change over time
(Figure 2A), and there was no correlation between
monocyte HLA-DR expression and PD-L1 expression
(Figure 2B). Analysis of PD-1 and PD-L1 expression over
time in septic patients revealed that expression of PD-1 on
CD8+ T cells increased as PD-L1 decreased during their
stay in ICU (Figure 2C). Furthermore, the subset of septic
patients with higher PD-1 together with lower PD-L1
expression on CD8 cells (‘CD8+ PD-1high PD-L1low’) in
which CD8+ PD-1 was ≥36% and CD8+ PD-L1was ≤5%
expression also had reduced levels of HLA-DR expression
on CD14+ monocytes compared with CD8+ PD-1low PD-
L1high septic patients (defined as CD8+ PD-1 ≤36% and
CD8+ PD-L1 ≥5% expression) and critically ill non-septic
patients (Additional file 5: Figure S3A). These values for
CD8+ PD-1high PD-L1low were chosen based upon the
mean values for CD8+ PD-1 and CD8+ PDL1 expression
for critically-ill non-septic patients. In other words, CD8+
PD-1 ≥36% and CD8+ PD-L1 ≤5% represented the values
for septic patients which were above the mean values
for CD8+ PD-1 expression and below the mean CD8+
PD-L1 expression for critically-ill non-septic patients.
This association of CD8+ PD-1 and PD-L1 expression with
HLA-DR expression was further validated by reciprocal
analysis of HLA-DR expression on CD14 monocytes.
In this setting, monocytes from septic patients which
had a <50% expression of HLA-DR had a higher pro-
portion of CD8+ PD-1high PD-L1low T cells than septic
patients with greater than 50% HLA-DR + monocytes
(data not shown). CD8+ PD-1high PD-L1low patient
samples were detected at all time points tested during
their septic condition, but increased over time (26.7%,
37.5%, 40% and 100% of samples per blood draw A to D
respectively). Interestingly, this same subgroup of septic
patients had an increased rate of secondary infections,
that is, ventilator associated pneumonia (VAP) and peri-
tonitis compared with other septic patients (P <0.05,
Additional file 5: Figure S3B). These data support the
idea that septic patients are a heterogeneous population
at different stages of disease and with differing immuno-
logic status upon presentation to the ICU, but develop
Figure 1 PD-1, PD-L1 and HLA-DR expression in septic and non-septic patients. Septic and non-septic patients were identified and heparinized
blood samples obtained at a maximum of four time points during their septic course. Peripheral blood mononuclear cells were stained for lymphocyte
(CD4, CD8) and monocyte markers (CD14). Immunostaining was also performed for programmed cell death 1 (PD-1), programmed cell death ligand 1
(PD-L1) and human leukocyte antigen-DR (HLA-DR). Flow cytometry revealed an increase in PD-1 and PD-L1 expression in CD8 T cells and monocytes
from septic versus non-septic patients. HLA-DR expression was decreased in monocytes from septic versus non-septic patients as well. Data
are from 43 septic (70 data points) and 16 non-septic patients (16 data points). Septic and non-septic patients had up to four serial blood
samples obtained depending upon the duration of their illness and/or discharge from the ICU; - first draw = days 1 to 3 after admission to the ICU, days
4 to 7 (second blood draw), days 8 to 12 (third blood draw), and days 13 to 21 (fourth blood draw) after sepsis onset. Most non-septic patients were
discharged from the ICU within four to five days and, therefore, they had less serial blood samples obtained compared to septic patients.
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protracted sepsis.Anti-PD-1 and anti-PD-L1 decreased sepsis-induced
apoptosis in lymphocytes
Apoptosis was quantitated in patient lymphocytes after
overnight incubation with isotype control antibody, anti-
PD-1 antibody or anti-PD-L1 antibody. Quantitation of
apoptosis in total lymphocytes, that is, all lymphocytes
present in the lymphocyte gate identified by forward and
side scatter on flow cytometry (Figure 3A) and consisting
primarily of CD4+, CD8+, NKT cells and NK cells was
examined. Total lymphocyte apoptosis was increased by
approximately 70% in septic patients when compared to
non-septic patients after overnight incubation in isotype
(inactive) control antibody, that is, 10.4 ± 1.5% in septic
patients versus 6.1 ± 2.1% in non-septic patients (P <0.01),
(Figure 4, Additional file 6: Figure S4). Compared to
lymphocytes incubated with isotype control antibody,
lymphocytes incubated in media containing anti-PD-1
or anti-PD-L1 antibody had a highly significant decrease
in apoptosis, P <0.001, (Figure 4). No effect of anti-PD-1
or anti-PD-L1 antibody on lymphocyte apoptosis was seen
in samples from non-septic patients, possibly due to their
lower level of baseline apoptosis which was often less
than 5%, (Figure 4). A highly similar effect of anti-PD-1
and anti-PD-L1 antibody on sepsis-induced apoptosis wasobserved in CD4 and CD8 T cells from septic patients
(Figure 4).Anti-PD-1/anti-PD-L1 ameliorate sepsis-induced
impairment in production of IFN-γ and IL-2
PBMCs from septic or non-septic patients were divided
equally into wells and incubated overnight with isotype
control antibody, anti-PD-1 antibody or anti-PD-L1 anti-
body. The next morning, cells were washed, stained for
various lymphocyte subsets and stimulated (see Methods).
Compared to non-septic patients, septic patients tended
to have persistently decreased intracellular production
of IFN-γ and IL-2 at multiple time points during the
course of their sepsis (Figures 3B and 5). This defect
occurred in total lymphocytes, CD3 lymphocytes and
NKT cells. Overnight incubation of PBMCs from septic
patients showed a significant effect of anti-PD-1 and
anti-PD-L1 antibodies to increase IFN-γ production
in total lymphocytes and NKT cells compared to cells
incubated with isotype control antibody (Figure 6).
Examination showed that a subset of patients’ samples
responded to anti-PD-1 or anti-PD-L1. Anti-PD-1 and
anti-PD-L1 had similar effects to increase IL-2 produc-
tion in specific lymphocyte subsets (Figure 7). Anti-
PD-1 and anti-PD-L1 had minimal effect on IFN-γ or
IL-2 production in lymphocytes from non-septic patients
(Figures 6 and 7).
Figure 2 Markers of immune exhaustion increase with protracted sepsis. Flow cytometry revealed an increase in expression of immune
exhaustion markers over time in the ICU. A) Monocyte PD-L1 expression was increased in septic patients compared to critically-ill non-septic
patients (CINS) patients. In contrast to changes in programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) expression on CD8 T
cells during sepsis, there was no change in the expression of PD-L1 during the septic time period. B) Comparison of monocyte PD-L1 expression
and human leukocyte antigen-DR (HLA-DR) expression did not show any correlation in patients with sepsis. (C) PD-1 expression increased as PD-L1
expression decreased on CD8 T cells in samples from septic patients over the course of their sepsis, that is, time points A (days 1 to 3), B (days 4 to 7), C
(days 8 to 12) and D (days 13 to 21). CD8 T cell PD-1 expression was higher in septic versus critically-ill non-septic patients (CINS). CD8 T cell expression of
PD-L1 fell to very low levels at time point D in septic patients compared to CINS patients and at time points A-C in septic patients. P-values in 2A and 2C
are comparison of septic samples with CINS for each draw.
Chang et al. Critical Care 2014, 18:R3 Page 6 of 15
http://ccforum.com/content/18/1/R3Correlation of apoptosis, absolute lymphocyte count and
PD-1 expression
A characteristic hematologic finding in patients with
sepsis is an apoptosis-induced reduction in their absolute
lymphocyte count (ALC), often to values that are less
than 20 to 30% of that for healthy controls [5,24,25].
Importantly, persistent lymphopenia in sepsis is associated
with increased mortality, and lymphocyte depletion (as
reflected by lymphopenia) may contribute to morbidity
and mortality by impairing host immunity [26,27]. There
are multiple mechanisms for the low ALC in sepsis,
including recruitment of lymphocytes to sites of infection
and apoptosis. We correlated lymphocyte apoptosis with
the ALC (Figure 8). Although there was no correlation
between ALC and lymphocyte apoptosis when samples
from all septic patients as a group were included
(Figure 8A), if the study population was restricted to
patients who had an ALC less than 1.2 × 103 cells/μL
blood (the lower limit of normal for ALC at our medical
center), there was a statistical correlation between low ALC
and the percent of lymphocytes undergoing apoptosis
(Figure 8B). In other words, septic patients with low ALCtend to have increased rates of lymphocyte apoptosis. In
order to examine the potential role for PD-1:PD-L1inter-
action in lymphocyte apoptosis, one possible cause of
lymphopenia in sepsis, we investigated the correlation
between PD-1 expression on CD4 and CD8 T cells and
absolute numbers of CD 4 and CD8 T cells. There was no
correlation between CD4 or CD8 PD-1 expression and
total numbers of CD4 or CD8 T cells or ALC (Figure 9A,
B and Additional file 7: Figure S5). Finally, we examined
the correlation of percent PD-1+ CD4 or CD8 T cells and
apoptosis as reflected by the degree of Tunel positivity.
At the first blood draw in septic patients, that is, days 1
to 3 after ICU admission (time point A), when lymphocyte
apoptosis was maximum (Additional file 6: Figure S4), there
was a correlation between the percent Tunel + CD4 T cells
and the expression of PD-1 on CD4 T cells (Figure 9C).
This correlation did not exist for CD4 or CD8 T cells at
other time points (Additional file 8: Figure S6).
Discussion
The present results show that blockade of either PD-1 or
its ligand PD-L1 reverses two pathophysiologic hallmarks
Figure 3 Representative flow histograms of lymphocyte gating strategy and detection of apoptosis and IFN-γ. Peripheral blood
mononuclear cells (PBMCs) from a septic patient were plated overnight with isotype control antibody, anti-programmed cell death 1 (PD-1) or
anti-programmed cell death ligand 1 (PD-L1) antibody. A: Cells were immunostained for CD4 and CD8 T cells and TUNEL assay performed. The
lymphocyte fraction in the PBMCs was identified by characteristic forward and side scatter properties and CD4 and CD8 T cells identified by
cell-specific antibodies. Apoptosis in CD4 T cells incubated in inactive isotype control antibody was 7.5%. Anti-PD-1 and anti-PD-L1 decreased
CD4 apoptosis to 1.25 and 2.0%, respectively. A similar protective effect was seen in CD8 T cells. B: PBMCs from a septic patient were incubated
overnight with isotype control antibody, anti-PD-1 or anti-PD-L1 antibody. The following morning, cells were stimulated with PMA/ionomycin plus
brefeldin for 5 h, washed, immunostained with phenotypic markers to CD3 and CD56, fixed and stained for intracellular interferon (IFN)-γ. The
lymphocyte gate was identified by characteristic forward and side scatter properties. Natural killer (NK) cells were identified as CD3 negative CD56
positive. The percentage of NK cells that were positive for IFN-γ that were incubated in inactive isotype control antibody was 9.9%. Treatment
with anti-PD-1 and anti-PD-L1 increased the percentage of NK cells that were IFN-γ positive to 34.8 and 21.8%, respectively.
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decreased sepsis-induce lymphocyte apoptosis and restored
the ability of immune effector cells to produce cytokines
that are essential for host immunity. These in vitro findings
in patient leukocytes strengthen the concept that blockade
of the PD-1:PD-L1 pathway offers a promising new ap-
proach in the treatment of sepsis [17,28]. Although
most previous therapeutic trials in sepsis have focused
on blockade of the initial hyper-inflammatory phase,
there is increased recognition that if patients survive
this initial stage of the disorder, they progress to an
immunosuppressive state [4,28-32]. New treatment proto-
cols have resulted in the fact that the majority of deaths
in sepsis now occur after the first four days of sepsis (the
hyper-inflammatory phase) and during the immunosup-
pressive phase [33]. Furthermore, microbiologic studies
of patients dying of sepsis showed that over 50% of theinfecting organisms were classified as opportunistic patho-
gens (opportunistic bacteria and fungi), a finding which
is highly compatible with impaired immunity [33]. In this
setting, use of immuno-adjuvant agents including anti-
PD-1 or anti-PD-L1 antibodies is a logical approach to
restore host immunity and potentially improve survival.
Research into the mechanistic basis of immunosuppres-
sion in sepsis has determined that multiple overlapping
etiologies exist including increased T regulatory and mye-
loid derived suppressor cells and apoptotic depletion of T
and B cells [5-8]. A relatively newly recognized etiology of
immunosuppression in sepsis is T cell exhaustion. T cell
exhaustion was first reported in animal models of chronic
viral infection and was thought to be due to persistent
exposure to high levels of antigen [9-11]. Patients with
sepsis often have a protracted course with primary and
secondary infections, a scenario that likely includes
Figure 4 Anti-PD-1 and anti-PD-L1 decrease lymphocyte apoptosis in sepsis. Peripheral blood mononuclear cells (PBMCs) from septic or
critically-ill non-septic (CINS) patients were incubated overnight in media containing isotype control antibody, anti-programmed cell death 1
(−PD-1) or anti-programmed cell death ligand 1 (−PD-L1) antibody. The following morning, cells were washed and underwent immunostaining
followed by detection of apoptosis via TUNEL assay. Compared to treatment with inactive isotype control antibody, incubation with anti-PD-1 or
anti-PD-L1 antibody decreased apoptosis in total lymphocytes, CD4 and CD8 T cells from septic patients; P <0.001. There was no significant effect
of anti-PD-1 or anti-PD-L1 in CINS patients, possibly due to the fact that baseline apoptosis in the non-septic patients was so low. Values shown
are the mean ± SEM values for all time points for 19 septic and 7 CINS patients. Circles indicate mean per group.
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development of T cell exhaustion [3,33,34]. A recent
postmortem study of spleens and lungs obtained from
patients dying of sepsis demonstrated findings highly
consistent with T cell exhaustion [3,10]. These findings
included severely depressed splenocyte cytokine produc-
tion, decreased T cell IL-7 receptor (CD127) expression,
and increased PD-1 and PD-L1 expression on T cells and
macrophages, respectively. These postmortem studies also
demonstrated that PD-L1 was highly expressed on tissue
parenchymal cells, that is, on splenic endothelial and
bronchial epithelial cells, thereby providing opportunity
for PD-1 activation [3]. Guignant and colleagues docu-
mented a correlation between PD-1 expression on circulat-
ing immune cells of septic patients and decreased T cell
proliferative capacity, increased nosocomial infections and
mortality [35]. Zhang et al. reported that anti-PD-1 was
increased on monocytes from septic patients and thatanti-PD-1 antibody decreased T cell apoptosis and improved
immune effector function [36]. A recent important study
by Singh et al. showed that in vitro blockade of PD-1
improved T cell IFN-γ production and decreased apoptosis
in patients with active infections due to M. tuberculosis
[37]. A second major finding of these investigators was
that when patients with active tuberculosis were treated
with effective medication to eradicate M. tuberculosis,
the number of PD-1-expressing T cells decreased and
inversely correlated with IFN-γ T-cell response against
M. tuberculosis. We believe that this work has major
implications for the broader field of sepsis because of the
similarities of active tuberculosis with protracted sepsis.
In addition to data that T cell exhaustion exists in
patients with chronic viral infections and sepsis, there
is evidence from animal studies that treatment with
anti-PD-1 and anti-PD-L1 antibodies can reverse T cell
dysfunction, increase pathogen clearance and improve
Figure 5 Sepsis impairs lymphocyte IFN-γ and IL-2 production. Peripheral blood mononuclear cells (PBMCs) from septic or critically-ill
non-septic (CINS) patients were incubated overnight in media containing isotype control antibody. Blood from septic patients was obtained at
three time points during the sepsis, that is, days 1 to 3 (Septic A), days 4 to 7 (Septic B) and days 8 to 12 (Septic C). Samples from days 13 to 21
(Septic D) were not tested. The following morning, cells were stimulated with PMA/ionomycin plus brefeldin for 5 h, washed, immunostained
with phenotypic markers to CD3 and CD56, fixed and stained for intracellular interferon (IFN)-γ or interleukin (IL)-2. Flow cytometric analysis
revealed a persistent decrease in the percentage of total lymphocytes and natural killer T (NKT) cells that were IFN-γ positive in septic compared
to CINS patients throughout most of the septic duration. The difference in IFN-γ production in septic versus CINS patients did not quite reach
statistical significance for CD3 T cells, P = 0.07. A similar pattern of decreased IL-2 production in septic versus CINS patients occurred at all septic
time points. Data are from 15 septic (21 data points) and 7 CINS patients (7 data points) obtained during their illness. P-values shown are comparison
of septic samples with CINS for each draw.
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blockade of the PD-1 pathway prevents apoptotic cell
death, restores host immunity and decreases mortality in
clinically-relevant models of bacterial and fungal sepsis
[16-20]. Given that T cell exhaustion is postulated to occur
after chronic antigen exposure, it is somewhat surprising
that anti-PD-1 and anti-PD-L1 antibodies were effective
in particular animal models of sepsis even though the
antibodies were administered relatively quickly after sepsis
began, that is, often within the first 24 to 48 h after sepsis
onset. These findings suggest either that other unidentified
PD-1 mediated immunosuppressive mechanisms arise
quickly after sepsis or that the term “exhaustion” shouldbe more narrowly restricted. Some investigators prefer
the term immune “reprioritization” rather than immune
“exhaustion” in this setting. Despite this controversy, the
present results showing that anti-PD-1 and anti-PD-L1
antibodies restore cytokine production and prevent apop-
tosis in immune cells from patients with sepsis are highly
consistent with these animal studies and underscore their
potential efficacy in clinical sepsis. The effect of anti-PD-1
and anti-PD-L1 to improve IFN-γ production by T cells
may be particularly beneficial in sepsis given its ability to
improve monocyte function, which is impaired in sepsis
[4,38,39]. A clinical trial of IFN- γ in sepsis is currently
underway and is being targeted to those patients whose
Figure 6 Anti-PD-1 and anti-PD-L1 antibodies increase IFN-γ production in sepsis. Peripheral blood mononuclear cells (PBMCs) from septic
or critically-ill non-septic (CINS) patients were incubated overnight in media containing isotype control antibody, anti- programmed cell death 1
(−PD-1) or anti- programmed cell death ligand 1 (−PD-L1) antibody. The following morning, cells were stimulated with PMA/ionomycin plus brefeldin
for 5 h, washed, immunostained with phenotypic markers to CD3 and CD56, fixed and stained for intracellular interferon (IFN)-γ. Flow cytometric
analysis revealed that, compared to inactive isotype control antibody, both anti-PD-1 and anti-PD-L1 antibody caused an increase in the percentage of
total lymphocytes and natural killer T (NKT) cells that were IFN-γ positive. Anti-PD-1 had no significant effect in CINS patients while anti-PD-L1 increased
IFN-γ in total lymphocytes only. Note that IFN-γ production was higher in CINS patients compared to septic patients when incubated with inactive
isotype control antibody. Data are from 15 septic patients (21 data points) throughout their illness - all blood draws. Values shown are mean ± SEM
values for all time points. Circles indicate mean per group.
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http://ccforum.com/content/18/1/R3circulating monocytes have low HLA-DR expression, (see
clinicaltrials.gov Trial number NCT01649921).
An important factor in the potential clinical utility of
anti-PD-1 or anti-PD-L1 antibodies in sepsis is identifying
which patients would be optimal candidates for blocking
therapy. Anti-PD-1 antibody has been highly successful in
a subset of patients with various types of malignancies
[14,15]. In general, those patients whose tumors expressed
PD-L1 on immunohistochemical analysis have responded
to therapy with anti-PD-1 antibody. As PD-1 and PD-L1
can also be early activation markers, it is inadvisable to
use these markers alone to diagnose an immunosuppres-
sive state. Currently, patients with sepsis whose monocytes
have decreased HLA-DR expression and/or patients whose
LPS-stimulated whole blood response shows decreased
TNF-α production are considered good candidates for
immuno-stimulatory therapy [4]. Increased CD8 T cell
PD-1 expression in conjunction with these two criteriamight identify patients who are good candidates for anti-
PD-1 antibody in sepsis. Recent studies, as well as work
from our own investigations, have shown that patients
with sepsis who have a persistently low absolute lympho-
cyte count have a greatly increased risk of dying of sepsis
[4, 6 and unpublished data]. We postulate that these
patients would be ideal candidates for anti-PD-1 antibody.
The positive correlation between PD-1 expression on CD4
T cells and apoptosis (Figure 9C), as well as the potent
anti-apoptotic effect of anti-PD-1 suggests that anti-PD-1
would be highly advantageous in this setting by acting to
increase lymphocyte numbers and function.
It is interesting to note that critically-ill non-septic
patients had increased expression of PD-1 on CD4 and
CD8 T cells (see Figure 1) compared to results in healthy
volunteers (unpublished data). In addition to sepsis, trauma
and major surgery are known to lead to a state of immuno-
suppression [5,28] and it is possible that PD-1:PD-L1 may
Figure 7 Anti-PD-1 and anti-PD-L1 antibodies increase IL-2 production in sepsis. Peripheral blood mononuclear cells (PBMCs) from septic or
critically-ill non-septic (CINS) patients were incubated overnight in media containing isotype control antibody, anti- programmed cell death 1 (PD-1) or
anti- programmed cell death ligand 1 (PD-L1) antibody. The following morning, cells were stimulated with PMA/ionomycin plus brefeldin for
5 h, washed, immunostained with phenotypic markers to CD3 and CD56, fixed and stained for intracellular interleukin (IL)-2. Flow cytometric
analysis revealed that, compared to inactive isotype control antibody, both anti-PD-1 and anti-PD-L1 antibody caused an increase in the
percentage of CD3 and natural killer T (NKT) cells that were IL-2 positive. Anti-PD-L1 had an effect to increase IL-2 production in total lymphocytes
and NKT cells in CINS patients. Note that IL-2 production was higher in CINS patients compared to septic patients when incubated with inactive isotype
control antibody. Data are from 15 septic patients (21 data points) throughout their illness. Values shown are the mean ± SEM values for all time points.
Circles indicate mean per group.
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as well. Conceivably, critically-ill non-septic patients who
have persistent elevation of lymphocyte PD-1 expression
and who are at high risk of infection might be candidates
for therapy with anti-PD-1 antibodies to boost their
immunity and prevent or ameliorate these infections.
A surprising finding was the potent effect of anti-PD-1
and anti-PD-L1 antibodies to increase production of IFN-
γ in NKT cells from septic patients (Figure 6). Sepsis
severely suppressed IFN-γ by NKT cells (Figure 5) and
both anti-PD-1 and anti-PD-L1 increased the percent
of IFN-γ positive T cells by approximately 50% in septic
patients (Figure 6). Although the data on the role of NKT
cells in sepsis are conflicting, recent studies indicate that
NKT cells bridge the gap between innate and adaptive
immunity and play an important role in response to
particular classes of pathogens, including Streptococcuspneumonia, a very common cause of community acquired
pneumonia [40]. NKT cells have also recently been shown
to play an important role in regulating peritoneal macro-
phage phagocytic function in a murine sepsis model
[41]. Therefore, these findings, showing a potent effect
of anti-PD-1 and anti-PD-L1 in patient PBMCs, are highly
relevant.
Anti-PD-1 and anti-PD-L1 antibodies have had extra-
ordinary success in cancer trials and are considered to
represent a major breakthrough in the field [42]. Anti-
PD-1 antibody induced remission in approximately 20
to 25% of patients with a diversity of tumors, including
malignant melanoma, renal cell cancer and non-small
cell lung cancer. A remarkable feature of anti-PD-1 and
anti-PD-1 therapy is the fact that some patients have
durable cancer remissions that last for many months in
the absence of continued therapy [43]. Cancer and sepsis
Figure 8 Correlation of absolute lymphocyte count and apoptosis. A low absolute lymphocyte count (ALC) is a frequent finding in sepsis and
correlates with outcome (see Discussion). We examined the relationship between ALC and apoptosis as determined by the Tunel assay. There was no
relationship of apoptosis (percent Tunel positive cells) and the ALC in septic patient considered as a whole (A). If the correlation of apoptosis and ALC
was restricted to septic patients who had an ALC below the lower limit of normal at Barnes Jewish Hospital (1.2 × 103 lymphocytes/μL blood), there
was a correlation such that patients with the lowest ALCs had the highest percent of Tunel + (apoptotic) lymphocytes. (B) There was a statistical
correction between ALC and lymphocyte apoptosis in septic patients who had an ALC less than 1.2 × 103 cells/μL blood (the lower limit of normal
at our hospital).
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including increased T regulatory cells, increased myeloid
derived suppressor cells, and T cell exhaustion [4-8,44].
This commonality in immune pathology in cancer and
sepsis could be due to the fact that both cancer and
sepsis may evolve into states of chronic low grade in-
flammation and persistent antigen exposure. Therefore,Figure 9 Correlation of PD-1 expression and absolute cell counts and
antibody decreased lymphocyte apoptosis (Figure 4), we investigated the c
absolute CD4 and CD8 T cells, respectively. Neither CD4 nor CD8 PD-1 exp
respectively. (C): We also investigated the correlation between PD-1 expres
PD-1 + CD4 T cells and the percent Tunel + CD4 T cells. At the time of the
correlation between PD-1 expression on CD4 T cells and the percent of apimmunotherapy that is effective in reversing immune
dysfunction in cancer might have similar effects in sepsis.
This finding could explain why anti-PD-1 and anti-PD-L1
are effective in these two seemingly disparate disorders.
Both anti-PD-1 and anti-PD-L1 antibodies have been
well tolerated in clinical trials to date [14,15,45]. Although
serious autoimmune reactions can occur in patientsapoptosis. (A and B): Since anti-programmed cell death 1 (PD-1)
orrelation between PD-1 expression on CD4 and CD8 T cells and
ression correlated with absolute (total) CD4 or CD8 T cell counts
sion and apoptosis by examining the relationship between percent
first blood draw in septic patients (days 1 to 3), there was a positive
optotic cells (Tunel+).
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reactions are uncommon. Patients with sepsis typically
may not require as prolonged a therapy with anti-PD-
1/anti-PD-L1 as patients with cancer. Therefore, severe
autoimmune reactions will likely be less of a problem
in patients with sepsis.
Conclusions
In conclusion, anti-PD-1 and anti-PD-L1 antibodies ame-
liorated key immune defects consistent with reversal of T
cell exhaustion in PBMCs from septic patients. Both anti-
bodies appeared equally effective in their capabilities. Thus,
lymphocyte PD-1 expression, in conjunction with other
cellular markers and clinical and laboratory findings,
may contribute to identifying septic patients in which
anti-PD-1 or anti-PD-L1 antibody therapy may be benefi-
cial. Collectively, the present findings indicate that T cell
exhaustion is a major etiology of immune dysfunction in
sepsis and that reversal of putative T cell exhaustion using
anti-PD-1 or anti-PD-L1 offers promise in the therapy of
this highly lethal disorder.
Key messages
 Sepsis induces an increase in the negative
co-stimulatory molecules PD-1 and PD-L1 on
patient immune effector cells.
 Blockade of the PD-1:PD-L1 pathway in septic
patient peripheral blood mononuclear cells
improved the ability of immune effector cells to
produce key cytokines and prevented apoptotic cell
death.
 Anti-PD-1 or anti-PD-L1 antibodies reverse
evidence of immune cell exhaustion in sepsis and
may represent a novel therapeutic approach to this
life threatening disorder.Additional files
Additional file 1: Table S1. Septic patients.
Additional file 2: Table S2. Critically ill non-septic patients.
Additional file 3: Figure S1. Lymphocyte PD-1 and monocyte PD-L1
expression quantitated by flow cytometry. Peripheral blood mononuclear
cells (PBMCs) from a critically-ill non-septic patient (CINS) and a septic
patient were stained for programmed cell death 1 (PD-1) and programmed
cell death ligand 1 (PD-L1). Lymphocytes were identified by their characteristic
forward and side scatter properties (see Figure 3). Monocytes were identified
by forward and side scatter properties and by CD14 immunostaining. The
gray curve represents the isotype control antibody. Note the increase in the
percent of lymphocytes that are PD-1 positive in septic vs CINS patients. The
geo mean fluorescent intensity (MFI) is also slightly increased in septic vs
CINS lymphocytes. There is also an increase in the percent of monocytes in
septic patients that are PD-L1+ and an increase in the MFI as well.
Additional file 4: Figure S2. Decreased monocyte HLA-DR in septic
patients. Peripheral blood mononuclear cells (PBMCs) from critically-illnon-septic (CINS) and septic patients had immunostaining for the monocyte
marker CD14 and for HLA-DR expression. Septic patients were followed
sequentially during their septic illness, that is, days 1 to 3 (septic A), days 4
to 7 (septic B), days 8 to 12 (septic C) and days 12 to 21 (septic D). Note the
decrease in monocyte HLA-DR expression in septic vs. CINS patients. Mean
per group is indicated by horizontal bar and represent the comparison of
septic samples with CINS for each draw. P-values shown are comparison of
septic samples with CINS for each draw.
Additional file 5: Figure S3. PD-1 and PD-L1 expression in sepsis as
markers of immunosuppression 3A. Since programmed cell death 1 (PD-1)
and programmed cell death ligand 1 (PD-L1) can also be activation markers,
data were further separated into a CD8+ PD-1high PD-L1low subset defined
as CD8+ PD-1 ≥36% and CD8+ PD-L1 ≤5% expression (n = 22 samples), and
a CD8+ PD-1low PD-L1high subset defined as CD8+ PD-1 ≤36% and CD8+
PD-L1 ≥5% expression (n = 47 samples), based on levels above the mean
CD8+ PD-1 and below the mean CD8+ PD-L1 expression for critically-ill
non-septic controls. None of the critically-ill non-septic (CINS) patient
samples were CD8+ PD-1high PD-L1low. Selection of septic patient
samples expressing high PD-1 and low PD-L1 on CD8+ T cells (CD8+
PD-1high PD-L1low, shown in boxed region) revealed a significantly
lower level of percent HLA-DR + CD14+ monocytes compared with the
CD8+ PD-1low PD-L1high subset, indicative of a generally more immune
suppressed state. Mean per group is indicated by the horizontal bars. 3B)
Septic patients were separated into CD8+ PD-1high PD-L1low and CD8+
PD-1low PD-L1high subsets based on PD-1 and PD-L1 immunostaining as
described above. Where multiple samples were drawn from patients over
the course of their ICU stay, samples were scored as positive only once.
Groups were analyzed for presence of more than two pathogens, secondary
infections, type and route of infection (VAP or peritonitis). The percentage of
patients positive for each parameter tested are shown for the CD8+ PD-1high
PD-L1low and CD8+ PD-1low PD-L1high subsets. This data analysis revealed
an increased number of secondary infections, VAP and peritonitis in septic
patients with a CD8+ PD-1high PD-L1low phenotype (n = 14 patients) compared
with a CD8+ PD-1low PD-L1high phenotype (n = 21 patients). VAP, ventilator
associated pneumonia; G pos, Gram positive; G neg, Gram negative.
Additional file 6: Figure S4. Sepsis induced lymphocyte apoptosis
quantitated by Tunel assay. Peripheral blood mononuclear cells (PBMCs)
from septic and critically-ill non-septic (CINS) patients were incubated
overnight and the following morning had immunostaining for CD4 and
CD8; apoptosis was quantitated by the Tunel assay. Note the increase in
apoptotic (Tunel +) lymphocytes (total lymphocytes identified by forward
and side scatter properties on flow cytometry), and in CD4 and CD8 T
cells in septic vs. CINS patients. The maximum time point for apoptosis is
during the first three days of sepsis (septic A). Mean per group is indicated
by horizontal bar. P-values shown are comparison of septic samples with
CINS for each draw.
Additional file 7: Figure S5. Lack of correlation of PD-1 expression and
absolute lymphocyte count in sepsis. Activation of the programmed cell
death 1 (PD-1): programmed cell death ligand 1 (PD-L1) signaling pathway
induces apoptosis in lymphocytes and thus may lead to a loss in absolute
lymphocyte count (ALC). Therefore, we examined if there was a correlation
between PD-1 expression on CD4 or CD8 T cells and the ALC. Freshly isolated
Peripheral blood mononuclear cells (PBMCs) were obtained from septic
patients throughout their septic illness and underwent immunostaining for
CD4, CD8 and PD-1 as described. Note that there was no correlation between
PD-1 expression on CD4 or CD8 T cells and the ALC.
Additional file 8: Figure S6. Lack of correlation of PD-1 expression and
total CD4 or CD8 T cell count. Given that programmed cell death 1 (PD-1)
can induce apoptosis of lymphocytes, we examined the correlation between
PD-1 expression on CD4 or CD8 T cells and the absolute numbers of CD4 or
CD8 T cells. Freshly isolated peripheral blood mononuclear cells (PBMCs)
were obtained from septic patients throughout their septic illness and
underwent immunostaining for CD4, CD8 and PD-1 as described. Although
there was a trend toward a correlation between PD-1 expression on CD4 T
cells and the total number of circulating CD4 T cells, that is, the total
number of circulating CD4 T cells was lowest in patients whose CD4 T
cells expressed PD-1, this correlation did not reach statistical significance,
(P = 0.12), there was no correlation between PD-1 expression on CD8 T cells
and the absolute numbers of CD8 T cells.
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ALC: Absolute lymphocyte count; CD: Cluster of differentiation;
CINS: Critically-ill non-septic; HLA-DR: Human leukocyte antigen-DR; IFN-
γ: Interferon gamma; IL-2: Interleukin 2; IQR: Interquartile range; NK: Natural
killer cells; NKT: Natural killer T cells; PBMCs: Peripheral blood mononuclear
cells; PD-1: Programmed cell death 1; PD-L1: Programmed cell death ligand
1; TCR: T cell receptor.
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